カンツズマブ
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/02/13 17:30:14」(JST)
[Wiki en表示]
Cantuzumab is a monoclonal antibody designed for the treatment of cancers. It is typically linked to one of several cytotoxic agents, yielding
- Cantuzumab mertansine
- Cantuzumab ravtansine
English Journal
- Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.
- Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, Howard M, Xie H, Tolcher AW.SourceInstitute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite #414, San Antonio, TX 78229, USA. jrodon@idd.org
- Cancer chemotherapy and pharmacology.Cancer Chemother Pharmacol.2008 Oct;62(5):911-9. doi: 10.1007/s00280-007-0672-8. Epub 2008 Feb 27.
- PURPOSE: Cantuzumab mertansine (SB-408075; huC242-DM1) is a conjugate of the maytansinoid drug DM1 to the antibody huC242, which targets CanAg antigen. In previous studies, cantuzumab mertansine was considered safe and tolerable, but transaminitis precluded tolerance of higher doses. Based on those
- PMID 18301896
- Gateways to clinical trials.
- Bayés M, Rabasseda X, Prous JR.AbstractGateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.com. This issue focuses on the following selection of drugs: ABX-IL-8, Acclaim, adalimumab, AGI-1067, alagebrium chloride, alemtuzumab, Alequel, Androgel, anti-IL-12 MAb, AOD-9604, aripiprazole, atomoxetine hydrochloride; Biphasic insulin aspart, bosentan, botulinum toxin type B, bovine lactoferrin, brivudine; Cantuzumab mertansine, CB-1954, CDB-4124, CEA-TRICOM, choriogonadotropin alfa, cilansetron, CpG-10101, CpG-7909, CTL-102, CTL-102/CB-1954; DAC:GRF, darbepoetin alfa, davanat-1, decitabine, del-1 Genemedicine, dexanabinol, dextofisopam, dnaJP1, dronedarone hydrochloride, dutasteride; Ecogramostim, eletriptan, emtricitabine, EPI-hNE-4, eplerenone, eplivanserin fumarate, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, etoricoxib, ezetimibe; Falecalcitriol, fingolimod hydrochloride; Gepirone hydrochloride; HBV-ISS, HSV-2 theracine, human insulin; Imatinib mesylate, Indiplon, insulin glargine, ISAtx-247; L612 HuMAb, levodopa/carbidopa/entacapone, lidocaine/prilocaine, LL-2113AD, lucinactant, LY-156735; Meclinertant, metelimumab, morphine hydrochloride, morphine-6-glucuronide; Natalizumab, nimotuzumab, NX-1207, NYVAC-HIV C; Omalizumab, onercept, osanetant; PABA, palosuran sulfate, parathyroid hormone (human recombinant), parecoxib sodium, PBI-1402, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, pimecrolimus, PINC, pregabalin; Ramelteon, rasagiline mesilate, rasburicase, rimonabant hydrochloride, RO-0098557, rofecoxib, rosiglitazone maleate/metformin hydrochloride; Safinamide mesilate, SHL-749, sitaxsentan sodium, sparfosic acid, SprayGel, squalamine, St. John's Wort extract, synthetic human secretin; Taxus, telavancin hydrochloride, telithromycin, temoporfin, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate/emtricitabine, teriparatide, testosterone gel, TG-1024, tirapazamine, travoprost, travoprost/timolol; Valdecoxib, valganciclovir hydrochloride, voriconazole; Ximelagatran.
- Methods and findings in experimental and clinical pharmacology.Methods Find Exp Clin Pharmacol.2005 Apr;27(3):193-219.
- Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.c
- PMID 15834452
- Technology evaluation: cantuzumab mertansine, ImmunoGen.
- Smith SV.SourceAustralian Nuclear Science and Technology Organisation, Materials Engineering and Science, Menai, NSW 2234. svs@ansto.gov.au
- Current opinion in molecular therapeutics.Curr Opin Mol Ther.2004 Dec;6(6):666-74.
- ImmunoGen is developing cantuzumab mertansine, in which the CanAg antigen-targeted humanized antibody C242 is conjugated to the company's proprietary cytotoxic agent, DM1, using ImmunoGen's tumor-activated prodrug technology. Cantuzumab mertansine is undergoing phase II trials for the potential trea
- PMID 15663331
Related Links
- Cantuzumab mertansine is a humanized monoclonal antibody used to treat colorectal cancer and other types of cancer. It is linked to a cytotoxic agent, mertansine. Three phase I clinical studies had reported results by 2003.
- ... free encyclopedia. Jump to: navigation, search. Cantuzumab is a monoclonal antibody designed for the treatment of cancers. It is typically linked to one of several cytotoxic agents, yielding. Cantuzumab mertansine · Cantuzumab ravtansine ...
Related Pictures
★リンクテーブル★
[★]
- 関
- モノクローナル抗体
mab
[★]
カンツズマブメルタンシン、カンツズマブ・メルタンシン